A phase II study of the combination of docetaxel and bevacizumab for previously treated non-small cell lung cancer.

CONCLUSIONS: The combination of DOC and BV often resulted in serious neutropenia, suggesting that this regimen is difficult to tolerate.
PMID: 31179803 [PubMed - as supplied by publisher]

Source: Cell Research - June 9, 2019 Category: Cytology Authors: Shimizu T, Nakagawa Y, Asai Y, Tsujino I, Takahashi N, Gon Y Tags: J Int Med Res Source Type: research